Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916100539> ?p ?o ?g. }
- W2916100539 endingPage "590" @default.
- W2916100539 startingPage "581" @default.
- W2916100539 abstract "Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sought to analyse the antitumour activity and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma.We did a multicentre, international, retrospective cohort study of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib during any treatment line at 22 centres: 21 in the USA and one in Belgium. Eligibility required patients with histologically confirmed non-clear-cell renal cell carcinoma who received cabozantinib for metastatic disease during any treatment line roughly between 2015 and 2018. Mixed tumours with a clear-cell histology component were excluded. No other restrictive inclusion criteria were applied. Data were obtained from retrospective chart review by investigators at each institution. Demographic, surgical, pathological, and systemic therapy data were captured with uniform database templates to ensure consistent data collection. The main objectives were to estimate the proportion of patients who achieved an objective response, time to treatment failure, and overall survival after treatment.Of 112 identified patients with non-clear-cell renal cell carcinoma treated at the participating centres, 66 (59%) had papillary histology, 17 (15%) had Xp11.2 translocation histology, 15 (13%) had unclassified histology, ten (9%) had chromophobe histology, and four (4%) had collecting duct histology. The proportion of patients who achieved an objective response across all histologies was 30 (27%, 95% CI 19-36) of 112 patients. At a median follow-up of 11 months (IQR 6-18), median time to treatment failure was 6·7 months (95% CI 5·5-8·6), median progression-free survival was 7·0 months (5·7-9·0), and median overall survival was 12·0 months (9·2-17·0). The most common adverse events of any grade were fatigue (58 [52%]), and diarrhoea (38 [34%]). The most common grade 3 events were skin toxicity (rash and palmar-plantar erythrodysesthesia; five [4%]) and hypertension (four [4%]). No treatment-related deaths were observed. Across 54 patients with available next-generation sequencing data, the most frequently altered somatic genes were CDKN2A (12 [22%]) and MET (11 [20%]) with responses seen irrespective of mutational status.While we await results from prospective studies, this real-world study provides evidence supporting the antitumour activity and safety of cabozantinib across non-clear-cell renal cell carcinomas. Continued support of international collaborations and prospective ongoing studies targeting non-clear-cell renal cell carcinoma subtypes and specific molecular alterations are warranted to improve outcomes across these rare diseases with few evidence-based treatment options.None." @default.
- W2916100539 created "2019-03-02" @default.
- W2916100539 creator A5000997350 @default.
- W2916100539 creator A5003892243 @default.
- W2916100539 creator A5005321013 @default.
- W2916100539 creator A5012121791 @default.
- W2916100539 creator A5023152191 @default.
- W2916100539 creator A5024065466 @default.
- W2916100539 creator A5032422193 @default.
- W2916100539 creator A5033372450 @default.
- W2916100539 creator A5033486347 @default.
- W2916100539 creator A5034278848 @default.
- W2916100539 creator A5036213851 @default.
- W2916100539 creator A5041033274 @default.
- W2916100539 creator A5046123003 @default.
- W2916100539 creator A5049071296 @default.
- W2916100539 creator A5049546835 @default.
- W2916100539 creator A5054206895 @default.
- W2916100539 creator A5055738663 @default.
- W2916100539 creator A5058325420 @default.
- W2916100539 creator A5058542749 @default.
- W2916100539 creator A5059219836 @default.
- W2916100539 creator A5059451886 @default.
- W2916100539 creator A5059604250 @default.
- W2916100539 creator A5060348071 @default.
- W2916100539 creator A5062559413 @default.
- W2916100539 creator A5066635849 @default.
- W2916100539 creator A5066816851 @default.
- W2916100539 creator A5069923958 @default.
- W2916100539 creator A5072115484 @default.
- W2916100539 creator A5073593424 @default.
- W2916100539 creator A5074019658 @default.
- W2916100539 creator A5075656682 @default.
- W2916100539 creator A5080507578 @default.
- W2916100539 creator A5081597269 @default.
- W2916100539 creator A5083027775 @default.
- W2916100539 creator A5084523168 @default.
- W2916100539 creator A5085652006 @default.
- W2916100539 creator A5087836779 @default.
- W2916100539 creator A5088131964 @default.
- W2916100539 date "2019-04-01" @default.
- W2916100539 modified "2023-10-14" @default.
- W2916100539 title "Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study" @default.
- W2916100539 cites W2010991736 @default.
- W2916100539 cites W2037716205 @default.
- W2916100539 cites W2068059571 @default.
- W2916100539 cites W2074416418 @default.
- W2916100539 cites W2100945326 @default.
- W2916100539 cites W2111867681 @default.
- W2916100539 cites W2116095691 @default.
- W2916100539 cites W2147211461 @default.
- W2916100539 cites W2151355131 @default.
- W2916100539 cites W2153867442 @default.
- W2916100539 cites W2173523195 @default.
- W2916100539 cites W2233483325 @default.
- W2916100539 cites W2264682687 @default.
- W2916100539 cites W2284518822 @default.
- W2916100539 cites W2295971206 @default.
- W2916100539 cites W2415950182 @default.
- W2916100539 cites W2558408743 @default.
- W2916100539 cites W2560219063 @default.
- W2916100539 cites W2566832984 @default.
- W2916100539 cites W2616530946 @default.
- W2916100539 cites W2696846258 @default.
- W2916100539 cites W2735520635 @default.
- W2916100539 cites W2766126886 @default.
- W2916100539 cites W2770072380 @default.
- W2916100539 cites W2782594419 @default.
- W2916100539 cites W2794685945 @default.
- W2916100539 cites W2795003721 @default.
- W2916100539 cites W2796207353 @default.
- W2916100539 cites W2799597692 @default.
- W2916100539 cites W2804644564 @default.
- W2916100539 cites W2884857090 @default.
- W2916100539 cites W2890106399 @default.
- W2916100539 cites W2894492020 @default.
- W2916100539 cites W2898370664 @default.
- W2916100539 doi "https://doi.org/10.1016/s1470-2045(18)30907-0" @default.
- W2916100539 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6849381" @default.
- W2916100539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30827746" @default.
- W2916100539 hasPublicationYear "2019" @default.
- W2916100539 type Work @default.
- W2916100539 sameAs 2916100539 @default.
- W2916100539 citedByCount "113" @default.
- W2916100539 countsByYear W29161005392019 @default.
- W2916100539 countsByYear W29161005392020 @default.
- W2916100539 countsByYear W29161005392021 @default.
- W2916100539 countsByYear W29161005392022 @default.
- W2916100539 countsByYear W29161005392023 @default.
- W2916100539 crossrefType "journal-article" @default.
- W2916100539 hasAuthorship W2916100539A5000997350 @default.
- W2916100539 hasAuthorship W2916100539A5003892243 @default.
- W2916100539 hasAuthorship W2916100539A5005321013 @default.
- W2916100539 hasAuthorship W2916100539A5012121791 @default.
- W2916100539 hasAuthorship W2916100539A5023152191 @default.
- W2916100539 hasAuthorship W2916100539A5024065466 @default.
- W2916100539 hasAuthorship W2916100539A5032422193 @default.
- W2916100539 hasAuthorship W2916100539A5033372450 @default.